恒瑞医药：注射用SHR-A2102、阿得贝利单抗注射液、注射用SHR-1802收到药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received clinical trial approval for three drug candidates, indicating progress in its research and development pipeline [1] Group 1: Clinical Trial Approvals - The company’s subsidiaries have received approval from the National Medical Products Administration for clinical trials of SHR-A2102, Adebeli monoclonal antibody injection, and SHR-1802 [1] - SHR-A2102 is an antibody-drug conjugate targeting Nectin-4, with only one similar product approved globally [1] - SHR-1802 is a humanized monoclonal antibody developed by the company, with no similar products approved in China [1] - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by the company [1]